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epilepsy and their families: protocol for a
randomized controlled trial of Making
Mindfulness Matter©
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Abstract
Background: Epilepsy extends far beyond seizures; up to 80% of children with epilepsy (CWE) may have comorbid
cognitive or mental health problems, and up to 50% of parents of CWE are at risk for major depression. Past
research has also shown that family environment has a greater influence on children’s and parents’ health-related
quality of life (HRQOL) and mental health than epilepsy-related factors. There is a pressing need for low-cost,
innovative interventions to improve HRQOL and mental health for CWE and their parents. The aim of this
randomized controlled trial (RCT) is to evaluate whether an interactive online mindfulness-based intervention
program, Making Mindfulness Matter (M3), can be feasibly implemented and whether it positively affects CWE’s and
parents’ HRQOL and mental health (specifically, stress, behavioral, depressive, and anxiety symptoms).
Methods: This parallel RCT was planned to recruit 100 child-parent dyads to be randomized 1:1 to the 8-week
intervention or waitlist control and followed over 20 weeks. The intervention, M3, will be delivered online and
separately to parents and children (ages 4–10 years) in groups of 4–8 by non-clinician staff of a local community
epilepsy agency. The intervention incorporates mindful awareness, social-emotional learning skills, and positive
psychology. It is modeled after the validated school-based MindUP program and adapted for provision online and
to include a parent component.
Discussion: This RCT will determine whether this online mindfulness-based intervention is feasible and effective for
CWE and their parents. The proposed intervention may be an ideal vector to significantly improve HRQOL and
mental health for CWE and their parents given its low cost and implementation by community epilepsy agencies.
Trial registration: ClinicalTrials.gov NCT04020484. Registered on July 16, 2019.
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Introduction
Background and rationale {6a}
Epilepsy is a common debilitating condition
characterized by spontaneous, unprovoked seizures.
While the prognosis for seizure control is favorable, with
66 to 80% of children becoming seizure-free in the long
term [1, 2], it has long been recognized that the impact
of epilepsy extends far beyond seizures [3–5]. Unequivo-
cal evidence has shown that up to 80% of children with
epilepsy (CWE) may face cognitive, psychiatric, and/or
behavioral comorbidities, many of which go under-
recognized and untreated, leaving patients with signifi-
cant unmet mental health needs [6–9]. Importantly,
such comorbidities often have a greater negative impact
on health-related quality of life (HRQOL) and life out-
comes than do epilepsy-specific factors [10–13]. Neuro-
psychological comorbidities have also been shown to
increase the frequency of outpatient visits, emergency
department visits, and hospitalizations [14], and nega-
tively impact seizure control after epilepsy surgery, and
the response and tolerance to antiseizure medications
(ASMs) [15].
It is widely acknowledged that the current standard of
care is not adequately addressing emotional and
behavioral comorbidities in CWE [6–9]. “Again and
again it is pointed out that the comorbidities continue to
be under-recognized and undertreated and that patients
with epilepsy have significant unmet mental health
needs. Nonetheless, there is no indication that this dis-
appointing state of affairs will change anytime soon”
[16]. In addition, outpatient pediatric neurology visits
are focused on the diagnosis, classification, and treat-
ment of the seizures, without adequate time or other re-
sources to attend to the child’s or parents’ possible
unmet needs. This is an important component because
families of CWE fare worse than other families on qual-
ity of parent-child relationship, parenting confidence,
family functioning and stress, and parental psychopath-
ology [3]. Parents of CWE have poorer HRQOL, with up
to 50% of mothers of CWE at risk for clinical depression
and 58% of parents at risk for anxiety [17–19]. Notably,
our findings, along with those of others, point to family
environment as an important determinant for long-term
HRQOL; epilepsy-related factors, with the exception of
seizure control, are seldom associated with HRQOL and
mental health [12, 20–22]. It is therefore essential that
interventions target parents’ well-being and HRQOL as
well as the HRQOL and psychological well-being of
CWE.
Mindfulness-based interventions
Cognitive-behavioral therapies are increasingly popular
in adult health research but their applicability and
accessibility limit widespread use in CWE. Cognitive-
behavioral therapy and counseling are often adminis-
tered one-on-one, which is costly and often depend on
difficult-to-access specialized therapists; wait times in
Ontario, Canada, exceed 6 months [23]. Although there
is a risk that the mental health of children and youth
can deteriorate while waiting for service, little is done to
monitor wait time trends and their impact [23].
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Targeting psychiatric and behavioral comorbidities may
therefore be best accomplished through community or-
ganizations and in group settings. Mindfulness-based in-
terventions may provide an ideal vector to target unmet
mental healthcare needs in persons with epilepsy and
their families. These group-based interventions are deliv-
ered at low cost and by non-medical staff.
Mindfulness-based interventions are effective and
have been well-validated for several adult outcomes
including physical and mental health, social and emo-
tional well-being, and cognition. Meta-analyses cover-
ing a wide spectrum of clinical populations and non-
clinical populations report an overall medium effect
size of 0.50 to 0.59 across these outcomes [24]. In a
recent Cochrane review of psychological interventions
for people with epilepsy [25], three studies specifically
examined mindfulness-based techniques for adults
and determined positive outcomes on mental health,
HRQOL, and seizure outcomes [26–28]. There has
been far less research on mindfulness with children
and youth; the studies that have been done are pla-
gued with methodological limitations including small
numbers and lack of randomization or control groups
[29]. However, evidence to date indicates that mind-
fulness interventions for children and youth are feas-
ible, accepted, and enjoyed by participants [30, 31].
The few well-conducted studies on mindfulness inter-
ventions in children without physical health issues
have reported reduced symptoms of anxiety, depres-
sion, and stress, reduced maladaptive coping and ru-
mination, and improved behavioral and emotional
self-regulation and focus [29, 30, 32]. Furthermore, a
recent systematic review and meta-analysis [29] found
that mindfulness interventions were three times more
effective (relative to other interventions such as
cognitive-behavioral therapy) in alleviating psycho-
logical symptoms among children with clinically diag-
nosed neuropsychological disorders (such as anxiety,
learning disability, and externalizing disorders).
In addition to the benefits of programs that deliver
mindfulness interventions directly to children,
programs that target parents appear to be effective in
improving parental functioning and, in turn, promote
positive child outcomes [30]. Furthermore,
mindfulness-based interventions for parents of chil-
dren with chronic issues (attention deficit hyperactiv-
ity disorder, developmental delays, autism) have been
shown to be effective for lessening parental stress and
mental health problems. Improvements in parent-
child relationships and improved youth behavior man-
agement have also been found [33].
Neither the Cochrane review on the impact of
psychological treatments for people with epilepsy [25],
nor a recent systematic review on mindfulness
interventions in youth [29] found studies investigating
mindfulness management techniques for CWE. Despite
the paucity of studies of mindfulness interventions in
childhood epilepsy, there is converging evidence to
suggest studying a mindfulness-based intervention in
children and families with epilepsy is warranted. There
is research pointing to the effectiveness of mindfulness-
based interventions on psychological symptoms in adults
and children, especially in those with relevant clinical is-
sues similar to CWE [24, 25, 29].
Proposed intervention: Making Mindfulness Matter (M3)©
Based on the extant knowledge outlined above,
together with a critical review of the benefits of
psychological interventions, we propose a low-cost,
live online intervention targeting both CWE and their
parents. The intervention, Making Mindfulness Matter
(M3)©, is provided to parents and children and incor-
porates mindful awareness, social-emotional learning
skills, neuroscience, and positive psychology. M3 is
delivered by non-clinician staff from a local commu-
nity epilepsy agency, and integrates attitudes, skills,
and behaviors related to mindfulness and social-
emotional learning. Mindful awareness is paying at-
tention to our thoughts, feelings, bodily sensations,
and surrounding environment in the present moment.
Social-emotional learning refers to abilities such as
managing thoughts, regulating feelings and behavior,
making healthy choices, and taking the perspective of
others. The program is delivered over an 8-week
period with one 1.5-h session per week for parents
and one 1-h session per week for children. Parents
and children learn the same core principles: how our
brains work, stress and the brain, mindful breathing,
mindful sensing, mindful movement, perspective tak-
ing, optimism, and gratitude/acts of kindness. Within
the parent group, the emphasis is on applying the
principles and skills directly to parenting. The child
program is designed for children 4–10 years of age,
with each lesson including a variety of concrete ways
to teach children skills based on their age/develop-
mental level. The program has a standardized proto-
col, presentation slides, and scripts to be used by the
facilitators leading each session. Approximately 80–
85% of the program is related to learning about
mindfulness, practicing mindfulness, or applying
mindfulness. Table 1 provides a description of the
topics covered during each M3 session.
M3 was modeled after the school-based MindUP
program and augmented for provision interactively
online and to integrate a parent component. MindUP
has been used by over 6 million children in over 12
countries and has been validated in several studies
that produced evidence of significant improvement in
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perspective taking, emotional control, optimism, cog-
nitive control, and stress physiology [34–36]. Children
who received the MindUP program also demonstrated
greater improvements in self-reported symptoms of
depression and peer-rated aggression [34–36]. The
low-cost, online group delivery and facilitation by
non-clinician staff also allow the program to be scal-
able to communities across Canada and increases its
likely sustainability.
Objectives {7}
Our long-term goal is to improve the quality of life
of children with epilepsy and their family. The object-
ive of this pilot trial is to evaluate the feasibility of
utilizing Making Mindfulness Matter (M3)© as a non-
medical therapeutic, interactive online intervention for
children with epilepsy and their parents. Our central
hypothesis is that M3 will be successfully imple-
mented and will improve HRQOL and overall mental
health and well-being in CWE and their parents. We
plan to test our central hypothesis and accomplish
the overall goal of this trial by pursuing the following
specific objectives:
Primary objective:
1. To assess the feasibility of successfully
implementing Making Mindfulness Matter (M3)©
as a live online family intervention for children with
epilepsy (CWE) and their parents. Specifically, we
will evaluate
a. Study procedures (e.g., recruitment, attrition,
time to complete questionnaires),
b. Participant feedback and adherence to M3,
c. Intervention fidelity.
This information will be essential in preparing for a
subsequent multi-centered trial across Canada. Feasibil-
ity outcomes will be evaluated throughout the course of
the study, and the specific outcomes collected and evalu-
ated are presented in section “Outcomes {12}”.
Table 1 Topics covered during each M3 session
Session Outline
1 Topic: An introduction to the brain, breathing, and mindfulness
Description: The focus of session one is building a comfortable environment and introducing main concepts such as how the brain and
our thoughts and feelings work together, mindful awareness, and deep breathing. Parents also learn about neuroplasticity and the STOP
model of mindful parenting.
2 Topic: How our brains work under stress
Description: Session two teaches how the brain works under stress. Children and parents learn to further identify which part of their brain
is busy when they feel big emotions and how mindfulness and a brain break can calm their amygdala, so they can choose to respond,
rather than react to stressful situations.
3 Topic: Mindful awareness and mindful breathing
Description: The concept of mindfulness is further explored in session 3, with children learning what is mindful or unmindful thinking and
practicing how to be in the present moment. Parents learn about the effects of breathing on the brain and body and learn mindful
techniques to use with their child.
4 Topic: Mindful sensing
Description: Further practice at being in the moment, through mindful sensing, is the focus of session 4. Both parents and children
participate in a variety of activities using the five senses mindfully.
5 Topic: Mindful movement
Description: Mindful movement is the topic of session 5. Parents learn about the brain-body connection, and mindful awareness of their
body and their children’s body during parent-child interactions. Child also learns mindful awareness of their body including how good pos-
ture relates to good thinking.
6 Topic: Perspective taking
Description: Both parents and children learn how perspective taking is a skill they can practice and strengthen through mindful awareness.
Parents explore their child’s perspective through imagining their child is video recording all interactions and using that to understand how
they should act in similar situations. Children learn perspective taking through games, books, and video.
7 Topic: Choosing optimism and appreciating happy experiences
Description: Choosing optimism and appreciating happy experiences are the focal points of session seven, with parents discovering that
optimism can be learned and three techniques to be a more optimistic parent. Children learn about positive and negative thinking, how it
affects how we feel and mindful ways to think more positive and have a growth mindset.
8 Topic: Expressing gratitude and acts of kindness
Description: Using mindful awareness to practice gratitude and kindness are explored, with children participating in activities that
encourage being thankful, and doing acts of kindness for those around them. Parents similarly learn how gratitude and kindness are linked
to better mental health and stronger family relationships and that kindness starts with being kind to ourselves.
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Secondary objectives are to obtain preliminary data
regarding the impact of M3 on:
2. Children’s health-related quality of life (HRQOL);
3. Parents’ HRQOL;
4. Children’s (i) externalizing problems, (ii)
internalizing problems, (iii) adaptive skills, (iv)
executive function, and (v) severity of epilepsy; and
5. Parents’ (i) depression, (ii) anxiety, and (iii) stress.
All secondary outcomes (i.e., efficacy outcomes) will be
evaluated 0–2 weeks before the intervention (i.e.,
baseline), and 1-week after the intervention (i.e., immedi-
ate follow-up). Efficacy outcomes for the intervention arm
will also be evaluated 10 weeks after the intervention (i.e.,
Extended Follow-up). The timeline of assessment is pre-
sented in Table 2 and section “Participant timeline {13}”.
Trial design {8}
This is a pilot, parallel, partially nested randomized
controlled trial (RCT) comparing two arms:
intervention (M3) and waitlist control (i.e., treatment
as usual). Participants will be randomized 1:1 into
the intervention or control arm. This study will not
interfere with patients’ clinical care. The intervention
will be delivered online to groups of 4–8 on a
rolling basis to minimize wait times and allow for
timely access to the intervention for the waitlist
controls.























QOLCE-55 X X X
PCGRC X X
BASC-3 X X X
BRIEF X X X
SF-12 X X X
CESD-R X X X
GAD-7 X X X
PSI-4-SF X X X
Family APGAR X X X
GASE X X X
Demographics/clinical X X X
Weekly Parent Questionnaire X X X
Parent Pre-Post Assessment X X
Child Pre-Post Assessment Xa Xa
M3 Adherence checklist X X X
Quality of Implementation X X X
QOLCE-16 (if participant withdraws) X X
Abbreviations: BASC-3 Behavior Assessment System for Children Scale, 3rd edition, BRIEF Behavior Rating Inventory of Executive Function, CESD-R Center for
Epidemiological Studies Depression, Revised scale, Family APGAR Family Adaptability, Partnership, Growth, Affection, and Resolve, GAD-7 7-Item Generalized
Anxiety Disorder, GASE Global Assessment of the Severity of Epilepsy, PCGRC Patient-Centered Global Ratings of Change, PSI-4-SF Parenting Stress Index, 4th
edition Short Form, QOLCE Quality of Life in Childhood Epilepsy Questionnaire, SF-12v2 12-item Short-Form Health Survey
aWill be completed a few days before and a few days after the first and last M3 session
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Methods
Methods: participants, interventions, and outcomes
Study setting {9}
Participants will be recruited from the population of
children treated for epilepsy in Southwestern Ontario,
Canada by the Division of Neurology, Children’s
Hospital at London Health Sciences Center (academic
hospital) and the solo pediatric neurology practice in
Windsor, ON (community clinic). The intervention will
occur online.
Eligibility criteria {10}
The inclusion and exclusion criteria are listed below.
The clinical neurology teams will evaluate inclusion
criteria 1–3 and exclusion criteria 1–3; the research
coordinator will confirm all eligibility criteria in
communication with parents.
Inclusion criteria
1) Children aged 4 to 10 years;
2) Diagnosed with epilepsy a minimum of 6 months
ago, as per the International League Against
Epilepsy operational definition*;
3) Child has reasonable comprehension of spoken
language and can follow simple instructions;
4) Child and their parent** are willing to attend all
intervention sessions;
5) Child and their parent** have an adequate
understanding of English.
*Operational definition of epilepsy [37]:
1. At least two unprovoked (or reflex) seizures
occurring > 24 h apart, or
2. One unprovoked (or reflex) seizure and a
probability of further seizures similar to the general
recurrence risk (at least 60%) after two unprovoked
seizures, occurring over the next 10 years, or
3. Diagnosis of an epilepsy syndrome
**Parent: refers to parent or guardian self-
identifying as most responsible for child’s day-to-day
care.
Note: To participate in the online intervention, CWE
and their parents would require access to a reliable
internet connection and a computer and/or mobile
device. All possible efforts will be made to provide
families with a mobile device if needed. The proportion
of families that require a computer/mobile device and
internet connect will be recorded and reported as part of
our feasibility outcomes.
Exclusion criteria
1) Progressive or degenerative neurological disorder;
2) Other major comorbid non-neurological disorders
(e.g., cystic fibrosis, Crohn’s disease, diabetes, renal
failure);
3) Scheduled to undergo epilepsy surgery during study
period;
4) Child or parent regularly practices complementary
health interventions such as meditation;
5) Concurrent enrollment in other intervention trials.
Rationale for eligibility criteria The inclusion criteria,
particularly with respect to seizure control, initial levels
of HRQOL and mental health (e.g., anxiety, depression,
stress), and cognitive ability, are deliberately broad, and
we acknowledge that this may limit the possible
improvements observed following intervention.
However, we believe this is justified given that the
primary aim of this trial is to evaluate feasibility and to
provide initial data on the potential effect of M3 on key
outcomes. The impact of initial levels of HRQOL and
mental health problems will be evaluated through a
subgroup analyses, which will present an opportunity for
a future RCT to be designed to focus on participants
with poor HRQOL and mental health. Furthermore, the
intervention was modeled after the MindUp program
that is designed for all children (not just those with
neuropsychological comorbidities).
The age range of 4–10 years was chosen because the
intervention has been validated for this age group. We
recognize that study results will not generalize to
individuals diagnosed with epilepsy in adolescence.
Children with newly diagnosed epilepsy (e.g., diagnosed
less than 6 months ago) were excluded because this
period is marked with increased stress, uncertainty, and
changed family dynamic. Children with progressive or
degenerative conditions are expected to experience
deterioration in health and thus likely in HRQOL over
time. Major comorbid non-neurological conditions will
most likely continue to have a major impact on HRQOL.
Lastly, participants who regularly practice complemen-
tary health interventions such as meditation were also
excluded. The benefit of introducing M3 to this group
was thought to be minimal since such participants are
regular practitioners of mindfulness or other comple-
mentary health interventions.
Who will take informed consent {26a}
Consent is taken by the research coordinator,
experienced in working with children and their parents.
Parents of eligible children will be provided with a letter
of information (LOI) during their clinic visit or via mail,
explaining the objectives of the study and all study
procedures. A few days later, the research coordinator
will contact parents by telephone to discuss the study,
answer any questions, and obtain informed consent of
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those interested. Given the online delivery of the
intervention, completing the consent or assent forms in
person is not feasible. Parents will provide consent
electronically; they will be emailed an individualized link
to the consent form through Research Electronic Data
Capture (REDCap) [38]. Assent will be obtained from all
children aged 5 years and older by a member of the
research team over a phone or video call before the first
intervention session. The research team member will
sign the assent form electronically through REDCap.
The research coordinator/assistants are not part of the
child’s circle of care.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
None / not applicable; there are no plans for ancillary
studies not covered by the consent form.
Interventions
Intervention description {11a}
Intervention arm: Making Mindfulness Matter (M3)©
Child-parent dyads will participate in a standardized 8-
week program, Making Mindfulness Matter (M3)©, de-
scribed above in section “Proposed intervention: Making
Mindfulness Matter (M3)©”. The program will be deliv-
ered online using live, interactive sessions to groups of 4
to 8, for 1.5 h each week for the parent group and 1 h
each week for the child group. For each group, we will
aim to schedule the sessions in consecutive weeks and at
the same time and day of the week, though some flexi-
bility in scheduling will be allowed. Children and parents
will attend separate, online sessions and at the end of
the child session, the parent will be asked to join their
child online for a shared mindful exercise. The M3 pro-
gram will have separate sessions for younger and older
children; the content of the sessions will be the same
though the activities will be geared towards the partici-
pants’ age group. The research coordinator will deter-
mine, in discussion with the child’s parents, whether the
child is better suited to the younger or older age group
depending on the child’s developmental stage and cogni-
tive ability. Typically, the younger group will be com-
posed of children aged 4.00 to 6.99 years and the older
group will be composed of children aged 6.00 to 10.99
years.
Control arm: waitlist control Child-parent dyads
randomized to the control arm will continue treatment
as usual. They will complete the baseline and immediate
follow-up questionnaire at comparable times to families
in the intervention arm; they will not complete the Ex-
tended Follow-up questionnaire. These dyads will be
provided with the intervention at the next scheduled
session after they have completed the immediate follow-
up; the goal is to provide the intervention to controls as
soon as possible to avoid differential attrition between
the intervention and control arm. During the interven-
tion sessions, participants in the control arm will
complete all feasibility questionnaires before and after
each session, pertaining to the intervention and their sat-
isfaction with each session.
Explanation for the choice of comparators {6b}
Attention placebo control (APC) is preferable over
treatment as usual or waitlist control for psychological
interventions, to account for non-specific effects a group
setting may offer such as social support/social attention
[39]. However this design is rarely used in such trials
[40]. Two key challenges may explain why the theoret-
ical benefits of APCs have not been realized in practice
and informed our decision to not use an APC in this
current trial: (1) Disproportional drop-out has been doc-
umented; a study assessing a parent training program re-
ported 18% and 50% attrition in the intervention and
APC arms, respectively [40]. Furthermore, the reasons
for drop-out were different; parents in the APC dropped
out without reason or indicating a preference to be in
the intervention rather than the APC arm, while parents
in the intervention arm dropped out due to scheduling
issues. (2) Potential for an ethical issue in a APC arm
where participants’ comments and questions in discus-
sions show a risky misunderstanding of key topics re-
lated to parenting, which should be addressed but where
doing so is outside the protocol for the undirected dis-
cussion condition of the APC [40]. We view both these
challenges as very likely to occur in the epilepsy popula-
tion. Given that the aim of the current pilot trial is to
evaluate feasibility, we will utilize a waitlist control arm
and provide controls with the intervention as soon as
possible, to avoid differential attrition between the inter-
vention and control arm. For the subsequent full RCT,
we are exploring possible programs to utilize as APC
and are considering a cluster random allocation process
where all the eligible participants recruited from each in-
stitution would be randomized as a group (cluster) to ei-
ther the intervention or an APC arm where it is much
easier to ensure blinding of participants to reduce the
likelihood of uneven drop-out. Additionally, a specific a
priori protocol could be developed for the APC to in-
corporate strategies for addressing misinformation about
epilepsy.
Setting and delivery of the intervention
The program is delivered by non-clinician staff. We have
partnered with our local community epilepsy agency,
Epilepsy Southwestern Ontario (ESWO), whose staff will
be provided the training required to deliver the
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intervention. Facilitators from ESWO will be trained on
the M3 program by the team that created it, led by Dr.
Karen Bax. The training will be a 2-day online, inter-
active session following the standardized M3 training
manual. Following the training, the ESWO facilitators
will co-lead the program with one established trainer. At
the half point of each program, a half-day booster-
training session will occur online so that the program fa-
cilitators can extend their knowledge of the program
and any facilitation issues that arise can be addressed.
The intervention will be delivered online, and a total
of four facilitators will deliver each M3 session (two
facilitators for the parent group, and two for the child
group). Two research assistants will also be present for
each online session (one for the parent group, and one
for the child group). The role of the research assistants
will be to report on intervention fidelity (quality of
implementation; described below, in section “Outcomes
{12}”) and to assist with the research aspects of the
sessions (e.g., facilitating the process of parents
completing questionnaires online).
Criteria for discontinuing or modifying allocated
interventions {11b}
Adverse events, if any, are expected to be minor. There
are no planned intervention modifications and no
planned circumstances whereby participants will be
removed from the intervention by the trial investigators.
Participants may withdraw from the study and
intervention at any time.
Strategies to improve adherence to interventions {11c}
Attendance will be tracked each week; if a session is
missed, the research coordinator will contact the parent
inquiring about the circumstances and identify if the
trial investigators can provide any assistance to avoid
missing future sessions. Parents are encouraged to
utilize M3 skills outside of the scheduled intervention
sessions, by being provided with parent cards that have
extension activities (based on the theme of that week) to
practice. Adherence to practicing or using the skills
outside of the scheduled intervention sessions will be
tracked at the start of each session; parents complete a
questionnaire inquiring about the utilization of M3 skills
or what may have prevented the utilization of those
skills (see the supplementary file).
Relevant concomitant care permitted or prohibited during
the trial {11d}
Usual care for participants continues throughout the
trial. There is nothing prohibited.
Provisions for post-trial care {30}
Participants randomized to the control arm will be
provided with the intervention in the next scheduled
session, after they have completed the study. Adverse
events, if any, are expected to be minor. Standard care is
provided through the Ontario Health Insurance Plan.
Outcomes {12}
Each outcome is described below. Feasibility outcomes
(primary objective) will be evaluated throughout the
course of the study. Efficacy outcomes (secondary
objectives) will be evaluated 0–2 weeks before the
intervention (Baseline) and 1 week after the intervention
(Immediate Follow-up). Secondary outcomes for the
intervention arm will also be evaluated 10 weeks after
the end of the intervention (Extended Follow-up). The
timeline of assessment is presented in Table 2 and sec-
tion “Participant timeline {13}”.
Primary outcome: feasibility The primary objective of
the trial, to evaluate the feasibility of implementing the
intervention, will be assessed by evaluating (a) study
procedures, (b) participant feedback and adherence to
M3, and (c) intervention fidelity, as described below.
Study procedures will be evaluated by tracking (a) the
number of patients contacted, (b) participating rate, (c)
reasons and/or barriers for non-participation (such as
the proportion of families without an internet connec-
tion and/or a computer/mobile device), (d) attrition, (e)
participant burden (e.g., time to complete question-
naires), and (f) quality of questionnaire data (e.g., the
proportion of missing data).
Participant feedback and adherence to M3 will be
evaluated using three measures developed for this study
(see the supplementary file). The first measure, the
Weekly Parent Questionnaire, is completed online by
parents at the start and end of each session. At the start
of the session it asks about the utilization of M3 skills
outside of the scheduled intervention sessions over the
past week and whether any adverse events were
experienced by the parent or child. At the end of each
session, it asks about skills taught in that session and
suggestions for improvement. The second measure,
Parent Pre-Post Assessment, is completed online by par-
ents at the start and end of the M3 program and evalu-
ates understanding and utilization of the skills taught by
M3, as well as participants’ satisfaction with the online
program. The third measure, Child Pre-Post Assessment,
is completed by children with the help of a research as-
sistant through a video call prior to the first group ses-
sion and after the program is completed. The measure
evaluates children’s understanding of topics discussed in
the group, such as how our brain works when we are
upset and what mindfulness is. These questions will be
Puka et al. Trials          (2020) 21:922 Page 8 of 19
read to the children by the researcher and are rated on a
3-point scale as indicated by a smiling, neutral and
frowning face.
Intervention fidelity will be evaluated through two
measures developed for this study (see the
supplementary file). The first measure, M3 Adherence
Checklist, is completed online, at the end of each session
by facilitators and evaluates whether each planned task/
activity was completed, any modifications that were
made, problems that arose, and the facilitator's
satisfaction with the session and the online format. The
measure was designed to evaluate and document how
each intervention session ran and was received by
participants from the facilitators’ perspective. The
second measure, Quality of Implementation, is
completed online, at the end of each session by the
research assistants present at each session and evaluates
the facilitators’ presentation of materials, their
confidence, and effectiveness at presenting materials.
Children’s health-related quality of life The parent-
reported 55-item Quality of Life in Childhood Epilepsy
Questionnaire (QOLCE-55) [41–43] will be used to
evaluate the HRQOL of CWE. The QOLCE-55 generates
a total HRQOL score and four subscale scores evaluating
cognitive, emotional, social, and physical functioning.
Scores range from 0 to 100, with higher scores indicative
of better HRQOL. The primary interest will be the mean
total HRQOL score at the Immediate Follow-up (week
9), adjusting for the total HRQOL score at Baseline
(week 0).
Although the QOLCE is a widely used HRQOL
scale, no study has calculated the minimum clinically
important difference (MCID). Using the methods
described by Wiebe et al. [44], we will ascertain
meaningful change in HRQOL for the QOLCE-55
using the parent-reported Patient-Centered Global
Ratings of Change (PCGRC). This information will
allow us to calculate the MCID for the QOLCE-55,
and thereby identify the proportion of patients who
experience a clinically meaningful change following
intervention. The PCGRC consists of 5 items and asks
participants to indicate the amount of change experi-
enced relative to baseline in five areas (questions) that
correspond to the QOLCE subscales: overall HRQOL,
cognitive function (e.g., memory and thinking), emo-
tional well-being, social activities/well-being, and
physical activities/well-being. Ratings range from − 7
(a very great deal worse) through 0 (no change) to
+ 7 (a very great deal better).
If participants withdraw from the study, they will be
presented with the option of completing the parent-
reported QOLCE-16 [45, 46], an abbreviated version of
the QOLCE-55, at the regularly scheduled times
(Immediate and/or Extended Follow-up). The QOLCE-
16 is composed of 16 items and is a shortened version of
the QOLCE-55 and is estimated to take less than 5 min
to complete. This will be important to the intention-to-
treat analysis in an attempt to follow all randomized
participants.
Parent’s health-related quality of life The parent-
reported 12-item Short-Form Health Survey (SF-12v2)
[47] will be used. It is the most frequently used patient-
reported outcome in clinical trials [48] and has been
used most frequently in studies evaluating HRQOL of
parents of CWE [19]. The SF-12v2 generates a physical
and mental health summary score, and 8 subscales:
physical functioning, role-physical, bodily pain, general
health, vitality, social functioning, role emotional, mental
health. The primary interest will be the mean mental
and physical health summary score at the Immediate
Follow-up (week 9), adjusting for the mean score at
Baseline (week 0).
Children’s externalizing problems Externalizing
problems will be evaluated using the Externalizing
Problems scale of the Behavior Assessment System for
Children-Parent Rating Scale (BASC-3-PRS) [49]. This
composite scale is composed of the following subscales:
hyperactivelity, aggression, and conduct problems. We
will utilize the BASC-3 preschool version (validated for
children aged 2–5 years) and the BASC-3 child version
(validated for children aged 6–11 years). Children with a
T-score above 59 in a given scale are categorized as “at
risk” for that domain. To ensure that parents complete
the same version at each follow-up, and given that the
study will last approximately 5 months (e.g., 20 weeks),
children aged 5.792 years or older will be given the
BASC-3 child version, and those aged less than 5.792
years will be given the preschool version at each follow-
up. The primary interest will be the mean Externalizing
Problems T-score at the Immediate Follow-up (week 9),
adjusting for the mean score at Baseline (week 0).
Children’s internalizing problems Internalizing
problems will be evaluated using the BASC-3 Parent
Rating Scale [49] Internalizing Problems scale. This
composite scale is composed of the following subscales:
anxiety, depression, and somatozation. Children with a
T-score above 59 in a given scale are categorized as “at
risk” for that domain. As explained above, parents of
children aged 5.792 years or older will be given the
BASC-3 child version, and those parents with children
aged less than 5.792 years will be given the preschool
version at each follow-up. The primary interest will be
the mean Internalizing Problems T-score at the
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Immediate Follow-up (week 9), adjusting for the mean
score at Baseline (week 0).
Children’s adaptive skills Adaptive skills will be
evaluated using the BASC-3 Parenting Rating Scale [49]
composite Adaptive Skills scale. This composite scale is
composed of the following subscales: adaptability, social
skills, leadership, functional communication, and activ-
ities of daily living. Children with a T-score above 59 in
a given scale are categorized as “at risk” for that domain.
As explained above, parents of children aged 5.792 years
or older will be given the BASC-3 child version, and par-
ents of children aged less than 5.792 years will be given
the preschool version at each follow-up. The primary
interest will be the mean Adaptive Skills T-score at the
Immediate Follow-up (week 9), adjusting for the mean
score at Baseline (week 0).
Children’s executive function The parent-reported Be-
havior Rating Inventory of Executive Function (BRIEF)
scale will be used to evaluate children’s self-regulation of
cognition, emotion, and behavior [50]. We will utilize
the BRIEF-2 version (validated for children aged 5–18
years) and the BRIEF-P (preschool) version (validated for
children aged 2–6 years). These measures generate a glo-
bal executive composite, cognitive regulation index,
emotion regulation index, and behavior regulation index.
Children with T-scores above 60 in a given scale are cat-
egorized as “at risk” for that domain. To ensure that par-
ents complete the same version at each follow-up,
children aged 5.00 years or older will be given the
BRIEF-2, and those aged less than 5.00 years will be
given the BRIEF-P version at each follow-up. The pri-
mary interest will be the mean global executive compos-
ite T-score at the Immediate Follow-up (week 9),
adjusting for the mean score at Baseline (week 0).
Severity of children’s epilepsy Parents will rate the
severity of their child’s epilepsy using the Global
Assessment of the Severity of Epilepsy (GASE), a
single-item scale measured on a 7-point Likert-type
scale [51, 52]. Seven additional items will be asked to
validate parents’ response on the GASE; these ques-
tions will ask about the severity of seizures, intensity
of seizures, falls or injuries during seizures, severity of
period immediately after a seizure, amount of antiepi-
leptic drugs, side effects of antiepileptic drugs, and
interference of epilepsy or drugs with daily activities.
At baseline only, the child’s neurologist will also
complete the GASE and the additional seven items.
Seizure frequency will also be rated by parents
through two questions asking about the number of
seizures and number of seizure-free days in the past
30 days. The primary interest will be the parent-
reported mean GASE score at the Immediate Follow-
up (week 9), adjusting for the mean score at Baseline
(week 0).
Parent’s depression The Center for Epidemiological
Studies Depression, Revised Scale (CESD-R) is a widely
used self-reported checklist evaluating level of depressive
symptoms in adults [53, 54]. This 20-item measure gen-
erates an overall score for depressive symptoms, ranging
from 0 to 60, with scores above 16 indicating risk for de-
pression. The primary interest will be the mean depres-
sion score at the Immediate Follow-up (week 9),
adjusting for the mean score at Baseline (week 0).
Parents’ anxiety The 7-item Generalized Anxiety Dis-
order (GAD-7) scale evaluates parents’ self-reported
symptoms of anxiety [55]. The GAD-7 generates an
overall anxiety score ranging from 0 to 21, with scores
above 10 indicating moderate-severe anxiety. The pri-
mary interest will be the mean anxiety score at the Im-
mediate Follow-up (week 9), adjusting for the mean
score at Baseline (week 0).
Parents’ stress The Parenting Stress Index 4 Short-
Form (PSI-4-SF) – screens for stress in the parent-child
relationship, identifying dysfunctional parenting and
child adjustment problems [56]. This 36-item parent-
reported scale generates scores on three domains (Par-
ental Distress, Parent-Child Dysfunctional Interaction,
and Difficult Child), which combine to form a Total
Stress scale. Scores in the 81st percentile or higher are
indicative of high stress. The primary interest will be the
mean Total Stress score at the Immediate Follow-up
(Week 9), adjusting for the mean score at Baseline (week
0).
Sociodemographic and clinical characteristics Parents
will be asked to complete several questions on key
demographic characteristics of the family (such as
parents’ age, education, occupation, marital status) and
children (such as gender, age, and comorbidities), similar
to questions we have used successfully in previous
studies [12]. Parents will also complete the Family
Adaptability, Partnership, Growth, Affection, and
Resolve (Family APGAR) [57, 58]. This scale evaluates
satisfaction with family relationships in the following
areas: coping with problems, partnership, growth,
affection, and resolve; scores range from 0 to 10.
At baseline, neurologists will complete a short
questionnaire documenting clinical characteristics of
each patient’s epilepsy: severity of epilepsy, seizure type
and frequency, type of epilepsy syndrome, age at onset
and diagnosis, medication information, adverse effects,
and other comorbid conditions. Type of seizure and
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epilepsy or epileptic syndrome will be classified using
the International League Against Epilepsy’s 2017
classifications [59, 60].
Adverse events At the start of each M3 session parents
are asked whether they experienced any physical
discomfort, emotional discomfort or distress, or an
increase in problems in relationships with others, while
practicing any of the M3 skills in the past week (see
supplementary file). Parents are also asked if their child
experienced any unwanted negative events while
practicing any M3 skills in the past week.
Rationale for lack of child-reported measures The
majority of questionnaires will be completed by parents,
with few exceptions (e.g., clinicians’ report on clinical
characteristics, and children’s pre-post assessment of M3
skills). We acknowledge that children’s own perceptions
are important and that this trial will not capture chil-
dren’s perceptions of the intervention and its impact;
however, we believe this is reasonable for three reasons.
First and foremost, the primary objective of this pilot
RCT is not to evaluate effectiveness as reported by chil-
dren; the primary aim is to evaluate feasibility, focusing
on participant adherence and facilitators’ adherence and
quality of implementation. Second, questionnaires are
completed at home and given the children’s age (4–10
years), parents would undoubtably have to provide the
child with the questionnaires and likely assist, potentially
biasing their responses. Lastly, given the children’s age
(4–10 years), the choice of validated self-reported ques-
tionnaires is limited and it has been proposed that chil-
dren under the age of 8 years may lack the cognitive
maturity and verbal comprehension capacity to provide
self-reports [61]. We are evaluating ways to best incorp-
orate children’s self-reports in a subsequent large-scale
RCT of M3.
Rationale for short follow-up period A short follow-up
period was chosen for two reasons. First, the primary
objective of this pilot RCT is not to evaluate the long-
term effectiveness of M3. Second, the short follow-up
serves to minimize attrition in the control arm in two
ways: by providing controls with the intervention as
soon as possible, thereby keeping them interested and
engaged in the study, and second it allowed for blinding
of participants and facilitators to the study hypotheses,
as described below, in section “Who will be blinded
{17a}”. The intention is to evaluate longer term out-
comes in a subsequent large-scale RCT.
Participant timeline {13}
Parents will be able to complete all questionnaires
online via REDCap, or if preferred, using mailed
questionnaires. The baseline and follow-up question-
naires are estimated to take 90min to complete. Parents
will also be asked to complete a brief online question-
naire via REDCap at the start and end of each M3 ses-
sion pertaining to the content of the M3 sessions and
their experience with the intervention.
Figure 1 highlights participants’ progression through
the study. Two weeks prior to the first M3 session of the
intervention arm, participants will be sent the baseline
questionnaire and asked to complete it within 1 week,
which will allow for a 1-week buffer window prior to the
first M3 session for the intervention arm. Once the
Baseline questionnaire is completed, participants will be
randomized. One week after the last M3 session for the
intervention arm, all participants will be sent the Imme-
diate Follow-up questionnaire. Participants will be asked
to complete the questionnaire within 1 week, with the
goal of receiving all completed questionnaires within
2 weeks.
Participants in the intervention arm will be asked to
complete a similar questionnaire, the Extended Follow-
up, 10 weeks after the end of the M3 session. For partici-
pants in the control arm, the Immediate Follow-up ques-
tionnaire is the final follow-up questionnaire they
complete. To provide interested controls with the inter-
vention as soon as possible, those interested in receiving
the intervention will be placed in a queue and will be
able to join the next scheduled M3 sessions. Therefore,
M3 sessions may be composed of participants random-
ized to the intervention arm and/or controls who have
completed the study (completed Baseline and Immediate
Follow-up questionnaires). During the M3 sessions, all
participants will complete the same online question-
naires pertaining to the content of the M3 sessions and
their experience with the intervention. Once the inter-
vention ends, those who were randomized to the control
arm will not need to complete any follow-up question-
naires. Therefore, the role of the controls in the inter-
vention would be to simply honor the commitment for
everyone to receive the M3 sessions and to “fill” the
group (given that 4–8 participants are needed per
group). The advantage of including dyads randomized to
intervention and dyads previously randomized to the
control arm is that it will increase the pool of partici-
pants waiting to receive the intervention and thereby ex-
pedite the time it takes to fill each group. The other
advantage is that it would ensure that dyads randomized
to the control group will receive the intervention as soon
as possible and ameliorate attrition in the control group.
Sample size {14}
The sample size calculation was based on the results of
our pan-Canadian prospective cohort study of children
(aged 4–12 years) with newly diagnosed epilepsy [45].
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Fig. 1 Schematic of participant progress
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Two years after diagnosis, we observed the mean score
on the QOLCE-55 to be 76.4 with a standard deviation
of 14.5. To our knowledge, there are no estimates of
minimal clinically important difference (MCID) for the
QOLCE-55, and no intra-class coefficient estimates
available for the impact of group-based psychological in-
terventions in CWE. We therefore assumed a conserva-
tive ICC among participants in M3 of 0.10, an average
cluster size of 6, and aimed to detect a large effect size
(d = 0.8) [62], corresponding to a 11.6-point difference
on the QOLCE-55 between the two study arms. The
11.6 point difference is in line with the MCID found for
the adult equivalent HRQOL measure, the QOLIE-31
[44]. Using the method for a trial with a group-
administered intervention, a control arm with independ-
ent subjects, and 1:1 randomization [63], the study re-
quires 38 child-parent dyads in the intervention arm and
38 child-parent dyads in the control arm to have 80%
power and the 2-sided 5% significance level. We will aim
to recruit 100 child-parent dyads to account for a liberal
estimate of 24% attrition.
Recruitment {15}
Participants will be recruited from the population of
children treated for epilepsy in Southwestern Ontario
by the Division of Pediatric Neurology, Children’s
Hospital at London Health Sciences Center and the
single pediatric neurology practice in Windsor, ON.
The clinical neurology teams will identify all patients
meeting clinical eligibility criteria and will provide
their parents with a letter of information (LOI) that
explains the aims of the study and all study
procedures. The LOIs will be distributed by mail or
occasionally in person during the child’s regularly
scheduled epilepsy appointment for those patients due
for an appointment in the near future. A member of
the research team will subsequently contact parents
in a few days to explain the study objectives and
procedures, answer any questions, confirm eligibility,
and obtain informed consent.
Assignment of interventions: allocation
Sequence generation {16a}
Stratified block randomization will be used. Allocation
tables were developed by KP in STATA 13.1 through
the ralloc command using an allocation ratio of 1:1,
randomly permuted blocks of varying sizes, and
stratified by children’s age group (younger vs. older). We
stratified by child's age group because the intervention
will have separate sessions for younger and older
children, as described in section "Intervention arm:
Making Mindfulness Matter (M3)©".
Concealment mechanism {16b}
Randomization will be facilitated centrally through
REDCap. The allocation sequence was generated and
uploaded to REDCap by KP, who is not involved with
participant recruitment, scheduling or any other forms
of participant contact. This web-based system prevents
circumvention of the randomization process and ensures
allocation concealment.
Implementation {16c}
Randomization is stratified based on the child’s age
group, as described in section “Sequence generation
{16a}”. Randomization will occur as close as possible to
the intervention to minimize the delay between study
arm allocation and the delivery of the intervention.
Therefore, once informed consent is received, the
parent-child dyad will enter the queue for
randomization. Given that the intervention will be deliv-
ered in groups of 4 to 8, and assuming some attrition
and scheduling conflicts, once 12 to 16 participants per
stratum are in queue for randomization and available for
the scheduled date/time of the intervention, participants
may begin the study by receiving the Baseline question-
naires (as described in the paragraph below). If there are
controls who have completed the study and are in the
queue to receive the intervention, at least 9 participants
need to be in queue for randomization. This would en-
sure that a minimum of 4 participants are randomized
to the control arm, which is important to fulfill our obli-
gations to participants by providing all participants with
the opportunity to receive the intervention. It would be
ethically problematic if, for example, one participant is
randomized and they are allocated to the control arm;
this participant cannot be offered the intervention at the
end of the study because at least 4 participants are
needed to run the intervention sessions.
Once enough participants are ready to be randomized,
those in the queue for randomization will receive an
individualized link to the baseline questionnaire and
electronic gift card via email 2 weeks before the first
scheduled M3 session of the intervention arm. These
participants will have 2 weeks to complete the
questionnaire but will be asked to complete it within a
week, to allow for a 1 week buffer. A member of the
research team will also connect with the parent and
child to attain assent of the child, complete the child Pre
Assessment, and offer a short tutorial of how to use
Zoom (the video conferencing application) if the parent
is unfamiliar with this platform. Upon completion of the
online baseline questionnaire by parents, the research
coordinator will randomize participants via REDCap.
Those randomized to the intervention (and controls
who are in the queue for the intervention) will be
provided with instructions on how access the online
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sessions. Those randomized to the control arm will be
told that they will be placed in the next scheduled M3
sessions, after they complete the Immediate Follow-up
questionnaire. Participants who were unable to complete
the baseline questionnaire will be placed in the next
scheduled group of participants to be randomized. After
the M3 program is completed, the Research Coordinator
will contact the family again to have the child complete
the Post Assessment.
Assignment of interventions: blinding
Who will be blinded {17a}
Blinding of participants and program facilitators (i.e., the
staff delivering the M3 intervention) will be difficult
given the nature of the intervention. However, blinding
to study hypotheses will be achieved by explaining to
participants and program facilitators that the study aims
to evaluate the effectiveness of the intervention given to
all participants; however, some participants will receive
the intervention in the upcoming M3 session, whereas
others will receive the next scheduled M3 sessions. In so
doing, we hope to eliminate any biases associated with
the participants’ and program facilitators’ perception or
biases of being assigned to the intervention or control
arm. The data analyst evaluating efficacy outcomes (e.g.,
HRQOL, mental health) will be blinded.
Procedure for unblinding if needed {17b}
There is no requirement for emergency unblinding
procedures.
Data collection and management
Plans for assessment and collection of outcomes {18a}
All data and questionnaires are captured online using
REDCap. If needed, participants may request mailed
questionnaires, which would be subsequently entered
into REDCap by a member of the research team.
Feasibility outcomes are collected throughout the
course of the study (e.g., recruitment, randomization,
retention, and the assessment procedures) by the
research team. After each intervention session, the
research assistant and facilitators will complete
questionnaires on REDCap designed to assess
adherence and quality of implementation. Facilitators
will be emailed individualized links to the
questionnaire through REDCap, whereas research
assistants will be able to enter data directly on
REDCap. On the day of an intervention session,
participants will be emailed an individualized link
through REDCap with the questionnaire they must
complete before or at the start of the session and at
the end of the session; these questions pertain to the
content of the M3 sessions and their experience with
the intervention.
Similarly, with respect to efficacy outcomes (Baseline,
Immediate Follow-up, and Extended Follow-up ques-
tionnaire), participants will be emailed (through RED-
Cap) an individualized link to the questionnaire along
with an individualized link to a $25 gift card.
Individualized links will also be emailed through
REDCap to clinicians who would complete a short
questionnaire pertaining to the patient’s clinical
characteristics.
Plans to promote participant retention and complete
follow-up {18b}
If a session is missed, the research coordinator will
contact the parent inquiring about the circumstances
and identify if the trial investigators can provide any
assistance to avoid missing future sessions. If
randomized participants are not able to attend the M3
sessions, but would still be interested in completing the
Immediate and/or Extended Follow-up questionnaires,
they would be encouraged to do so. If participants with-
draw, the reasons will be recorded and they will be pre-
sented with the option of completing the parent-
reported QOLCE-16 [45, 46], an abbreviated version of
the QOLCE-55, at the Immediate and/or Extended
Follow-up, that is estimated to take less than 5 min to
complete. This will be important to the intention-to-
treat analysis in an attempt to follow all participants ran-
domized into one of the two study arms.
Data management {19}
All data are entered onto REDCap [38], a widely utilized
and secure web-based platform. The research team
evaluating the quality of implementation and other study
data undergo a 1.5-h training session and REDCap train-
ing. Data are held in a secure server at Lawson Health
Research Institute, London, Ontario, Canada. REDCap is
also utilized to randomize and email individualized ques-
tionnaire links to participants. Participants will not be
required to provide an answer to each question. A num-
ber of quality control procedures in REDCap were spe-
cifically created for this project and will be utilized, such
as providing participants with an ignorable warning that
some questions have been left blank to minimize the fre-
quency of missing questions. Other quality control pro-
cedures include providing warning or reminder
messages to the research team (e.g., indicating that a
participant is not eligible), preventing certain actions
(e.g., preventing the randomization of participants unless
all inclusion criteria are met and the Baseline question-
naire is completed), notifying the research team if ad-
verse events are reported or if questions have been left
blank, and tracking participants’ progression through the
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study and the time it took participants to complete each
questionnaire. Once participants have completed their
questionnaire, a research assistant will be notified by
REDCap and subsequently review the responses and
follow-up with participants if needed. If the participant
requested paper questionnaires, the data will be reviewed
and entered in REDCap by a research assistant.
Confidentiality {27}
REDCap servers follow hospital security guidelines and
policies and all the web-based information transmission
is encrypted. REDCap was developed specifically around
Health Insurance Portability and Accountability Act
(HIPAA)-Security guidelines and is recommended to re-
searchers by Privacy Offices and Institutional Review
Boards of many organizations.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
No biological samples will be collected.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Descriptive statistics will be run with continuous
variables summarized using means and standard
deviations and categorical variables summarized using
frequencies and proportions. To evaluate study
feasibility, descriptive statistics will be used to
summarize study procedures among all participants,
including (a) number of families contacted, (b)
participation rate, (c) reasons and/or barriers for non-
participation, (d) attrition rate, (e) time to complete
questionnaires, and (f) missing data on questionnaires.
To evaluate (1) participant feedback and adherence to
M3 and (2) intervention fidelity, data from the interven-
tion and control arms will be combined and descriptive
statistics used to describe responses to the Weekly Par-
ent Questionnaire, Parent Pre-Post Assessment, and
Child Pre-Post Assessment, M3 Adherence Checklist,
and Quality of Implementation questionnaire.
To evaluate Efficacy Outcomes (e.g., HRQOL), we will
use linear mixed models, which are suitable for group-
administered interventions to account for the clustering
in the intervention arm and no clustering in the control
arm [63, 64]. The primary interest will be comparing the
mean scores of the intervention and control arms at the
Immediate Follow-up (e.g., HRQOL 1-week post-M3),
adjusting for potential imbalance at Baseline (e.g.,
HRQOL pre-M3). Given that age group (younger vs.
older) was a variable used in stratifying randomization,
analyses will adjust for age group.
Similarly, generalized linear mixed models will be used
to evaluate whether the intervention and control arms
differ with respect to the proportion who show clinically
significant improvement, and the proportion with
clinically elevated symptoms post-intervention [65].
Interim analyses {21b}
There will be no interim analyses.
Methods for additional analyses (e.g., subgroup analyses)
{20b}
Two sensitivity analyses are planned. First, to evaluate
whether outcomes at the Immediate Follow-up (1 week
post-M3) are retained or changed over the longer term
(10-weeks post-M3), linear mixed models will be used to
evaluate outcomes at each time point (Baseline, Immedi-
ate Follow-up, Extended Follow-up) for participants ran-
domized to the intervention arm. Second, we do not
plan to adjust for any covariates (other than age group
and the value of the outcome variable at baseline), but
may consider adjusting for variables that are substan-
tively imbalanced between the study arms within the
sensitivity analyses.
Lastly, adverse events will also be evaluated. Data from
the intervention and control arms will be combined and
descriptive statistics will be used to evaluate the
frequency of adverse events, based on parents’ reports at
the start of each M3 session. All collected adverse events
will be reported.
Methods in analysis to handle protocol non-adherence and
any statistical methods to handle missing data {20c}
Analysis will follow the intention-to-treat principle. We
do not plan to impute missing values, but may consider
use of multiple imputation or other strategies within the
sensitivity analysis.
Plans to give access to the full protocol, participant-level
data, and statistical code {31c}
The current document outlines the full protocol. Non-
identifiable data may be made available in response to a
reasonable and well-motivated request to the principal in-
vestigator. Data cannot, however, be made freely available
to the public, due to privacy regulations and informed con-
sent. A data sharing agreement will also need to be signed.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d}
The research team is multi-disciplinary, spanning epi-
demiology (KNS, KP), biostatistics (GZ, KP), pediatric
neurology (AA, CC, MDR, HG, SL, MNN, ANP), clinical
psychology (KB), and knowledge translation (MS). The
immediate trial team (KS, KB, KP, and research
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coordinators) will oversee all aspects of the study, such
as internal monitoring of the trial data and training of
staff. The immediate trial team meets weekly or more
frequently as needed to oversee the project and monitor
progress. KB, a clinical psychologist, will be automatic-
ally made aware (via REDCap notifications) of any ad-
verse events reported by parents and, if needed, will
contact and follow-up with participants.
Composition of the data monitoring committee, its role and
reporting structure {21a}
The immediate trial team (KS, KB, KP, and research
coordinators) meets weekly or as needed to oversee the
project and monitor progress. The main goal will be to
evaluate study procedures and identify the need for any
adjustments (such as recruitment procedures). Given
that adverse events, if any, are expected to be minimal,
an independent data monitoring committee was not
deemed necessary.
Adverse event reporting and harms {22}
As indicated previously, adverse events, if any, are
expected to be minor. At the start of each M3 session
parents will be asked whether they experienced any
physical discomfort, emotional discomfort or distress, or
an increase in problems in relationships with others,
while practicing any of the M3 skills in the past week.
Parents will also be asked if their child experienced any
unwanted negative events while practicing any M3 skills
in the past week. KB, a clinical psychologist, will be
automatically made aware of any adverse events
reported by parents and, if needed, will contact and
follow-up with participants. With respect to reporting
adverse events, data from the intervention and control
arms will be combined and descriptive statistics will be
used to evaluate the frequency and severity of adverse
events. All collected adverse events will be reported.
Frequency and plans for auditing trial conduct {23}
No audits have been planned. The immediate trial team
(KS, KB, KP, and research coordinators) meets weekly or
as needed to oversee the project and monitor progress.
Plans for communicating important protocol amendments
to relevant parties (e.g., trial participants, ethical
committees) {25}
Version control using protocol identifies and dates
will be used. The research ethics board will approve
amendments and substantive changes will be noted
on clinicaltrials.gov and/or subsequent journal
publication(s).
Past protocol versions This manuscript is based on
protocol version 3.0. In Version 3.0, the intervention was
modified to be delivered interactively online, as a result
of the COVID19 pandemic. Twelve participants were
randomized prior to protocol version 3.0 and
participated in the in-person intervention. Data from
these participants will not be combined with future par-
ticipants who complete the intervention online. A new
randomization list was generated for participants partici-
pating in the online intervention, and a total of 100 will
be randomized.
In Version 2.0, the operational process was modified
for a pragmatic reason to increase the pool of
participants waiting to receive the intervention and
thereby expedite the time it takes to fill each group (as
described in section “Participant timeline {13}”). The
original process (in Version 1.0) was more restrictive
and used a stringent timeline, requiring that the
intervention arm receives the intervention in weeks 1–8
and the control arm receives the intervention in weeks
10–17. This limited the participant pool because eligible
participants had to be available during weeks 1–8 and
weeks 10–17 (given that they could have been
randomized to either group).
Dissemination plans {31a}
We will develop a publication and dissemination plan to
include conference presentations and journal
publications. We plan to write to all participants to
inform them of the trial results. We will also plan
dissemination to relevant patient and clinical interest
groups.
Discussion
This protocol describes a funded pilot RCT evaluating
the feasibility of implementing an interactive online
mindfulness-based intervention for CWE and their par-
ents. To the best of our knowledge, this is the first be-
havioral intervention targeting young children with
epilepsy which is particularly important as evidence to
date suggests that early identification and treatment of
epilepsy comorbidities are essential as there may be a
window of opportunity for early intervention in some
children [66, 13]. Interventions must be implemented
early before problems become entrenched and interfere
with the development of basic cognitive, behavioral, and
social skills crucial for long-term educational, vocational,
and interpersonal adaptation. In addition, interventions
(such as M3) targeting self-regulation and executive
functioning may be most effective during the preschool
and early school years given the ongoing brain develop-
ment and maturation of children in this age group [67,
68]. M3 is also unique because the intervention is deliv-
ered to parents and children, providing parents and their
child with a common vocabulary and skillset, and enab-
ling them to jointly practice the skills learned. Lastly, we
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believe that this program provides an ideal vector to tar-
get the unmet mental health care needs of CWE and
their parents, given that the program may be delivered
by non-clinical staff and is delivered online in a group
setting. These characteristics would allow the interven-
tion to be implemented at low cost and by epilepsy sup-
port centers, allowing scalability to communities across
the country and increasing its likely sustainability.
The primary goal of this RCT is to evaluate feasibility,
with respect to participant adherence and the quality
with which facilitators are able to implement the
intervention. Additionally, the feedback received from
the recruitment, randomization, retention, and
assessment procedures, as well as the feedback from
parents and facilitators will allow us to better implement
this intervention in a subsequent, larger multicenter
trial. The data collected will also allow for the
calculation of the MCID in HRQOL scores and enable
better estimates of the impact of the intervention on key
outcomes. This information will be necessary for robust
sample size calculations. In reaching these feasibility goals,
this study will employ a short follow-up period, comparing
the intervention and control arm immediately after the
intervention. This short follow-up may make it difficult to
identify significant improvements in HRQOL, which may
take some time to develop. However, participants in the
intervention arm will also report on outcomes 10 weeks
after the intervention, to estimate a longer-term effect. Im-
provements in other domains, such as depression, anxiety,
executive function, and stress, may be evident in the short
term. Regardless, the information obtained from these
measures will be essential in the development of our sub-
sequently large-scale RCT.
Trial status
Recruitment is ongoing. Potential participants were first
identified and entered on REDCap on November 12,
2019, and LOI were first mailed to participants on
November 28, 2019. The protocol was modified for
online delivery of the intervention on September 21,
2020, and the first online intervention session is
anticipated on October 2020. The trial is scheduled to
end on September 2022.
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